Targeting fundamentals of inflammation, autoimmunity and fibrosis

TRANSFORM

inflammatory, autoimmune and fibrotic diseases
DIFFERENTIATE

by targeting emerging central disease biology nodes
IMPACT

via selective depletion of pathogenic cells

Item 1 of 3

Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.

GRT-001

Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.
GRT-002

Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.

Two first-in-class therapeutic antibodies GRT-001 and GRT-002

2000

20 years of foundational research

In novel approaches for inflammation and fibrosis

2021

Lead assets and pipeline growth

Foundation of Granite Bio by Versant Ventures and Novartis Venture Fund (NVF), integrated into the Ridgeline Discovery Engine. 30 Million USD Series A Financing

2022

Preclinical Development/CMC

Development Candidates achieved.

2023

Series B & CTA submission

70 Million USD Series B Financing led by Forbion and Sanofi ventures, completion of CTA enabling studies and CTA submission.

2024

Phase 1 / 1b

Clinical trial approval by the German health authorities (Paul-Ehrlich-Institute, PEI) to initiate Ph1(b) trial of GRT-001 in healthy volunteers and patients with inflammatory bowel disease (IBD). First Ph1 participants dosed March 6 at CRO Charité Berlin, Germany.

2025

Phase 1b / IBD & Team-growth

Finalizing Ph1a SAD in healthy volunteers; bridging into adaptive biomarker-guided Ph1b trial in IBD (ulcerative colitis). Team expansion: Patrick Loustau joins as President and CEO, Gijs van den Brink as CSO, Eliot Forster as Chairman of the Board.